To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics™ Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.
Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.
Dr. Scott Rodig is a hematological pathologist at Brigham and Women’s Hospital in Boston, MA. He has had a long interest in untangling the complex interactions among Hodgkin’s tumors and their associated stroma to both gain insights into the tumor pathogenesis as well as to develop novel tissue biomarkers for tracking these cells. Much of Dr. Rodig’s research is made possible with Phenoptics™.